

Special Issue

Lymph Node Dissection in Colorectal Cancer

Message from the Guest Editor

Colorectal cancer (CRC) has been diagnosed at an early stage more frequently due to the recent advances in endoscopic techniques. Even for patients with early-stage CRC, clinicians must consider the type of treatment and the depth of submucosal invasion is considered the most important factor in determining a suitable treatment strategy. Surgical resection of CRC is the cornerstone of the treatment. However, the incidence of anastomotic leakage (AL) is high, and the postoperative mortality is therefore high due to AL. There is a general consensus that comorbidities play a crucial role in the outcome of the surgery. Recent reports have suggested that older patients with certain risks could be overtreated. Overtreatment results in the possibility of subsequent excess morbidity and mortality.

Patients also need to consider radical resection, oncological resection, and surveillance. Therefore, accurate risk stratification and predictive tools are highly valued to help them in this decision-making process. Here, we discuss the risk factors of LNM in CRC patients and the technology, strategy, and the future. In this Special Issue, original research articles and reviews are welcome.

Guest Editor

Dr. Norikatsu Miyoshi

Department of Surgery, Osaka International Cancer Institute, 3-1, Otemae, Tyuou-ku, Osaka 541-8567, Japan

Deadline for manuscript submissions

closed (31 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/154248

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)